The startup develops non-invasive immunodiagnostic kits utilizing a multiplex biomarkers panel with high sensitivity and specificity for bladder cancer diagnosis and monitoring. This technology provides researchers with accurate and conclusive testing results, enhancing the reliability of bladder cancer assessments.
Funding
$4.2M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Current methods for bladder cancer diagnosis and monitoring, such as cystoscopies and urine cytology, are either invasive, costly, or lack sufficient sensitivity and specificity. This creates challenges for accurate and timely detection, especially for patients with hematuria or a history of bladder cancer. The need for frequent monitoring also places a burden on both patients and healthcare systems.
Solution
BioCheetah provides non-invasive immunodiagnostic solutions for bladder cancer detection and monitoring, utilizing a multiplex panel of proprietary protein biomarkers discovered through quantitative proteomics. Their flagship product, VECanDx™ ELISA, is an in-vitro diagnostic test that employs standard ELISA procedures to detect these biomarkers in urine samples with high accuracy. By combining these biomarkers with a proprietary algorithm, BioCheetah aims to offer a more accurate and less burdensome method for detecting bladder cancer, allowing for better patient triage and more effective use of clinical resources. A point-of-care testing (POCT) kit is also under development for rapid qualitative analysis.
Target Audience
The primary target audience includes hospitals, laboratories, general practitioners (GPs), and polyclinics involved in the diagnosis and management of bladder cancer, particularly those seeking non-invasive and accurate diagnostic tools.
Features
- VECanDx™ ELISA IVD test kit for non-invasive detection of bladder cancer in hematuria and recurrent bladder cancer patients
- Utilizes a multiplex of five proprietary protein biomarkers specific to bladder cancer
- Employs standard ELISA procedures for biomarker detection and quantification
- Proprietary algorithm for improved accuracy and conclusive testing results
- Point-of-Care Testing (POCT) kit (in development) for rapid qualitative analysis
- Designed for early-stage screening of bladder cancer
- Intended to provide high sensitivity and specificity for early and late stages of bladder cancer